GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LENZ Therapeutics Inc (NAS:LENZ) » Definitions » Short-Term Debt

LENZ (LENZ Therapeutics) Short-Term Debt : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is LENZ Therapeutics Short-Term Debt?

LENZ Therapeutics's Short-Term Debt for the quarter that ended in Dec. 2024 was $0.00 Mil.


LENZ Therapeutics Short-Term Debt Historical Data

The historical data trend for LENZ Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENZ Therapeutics Short-Term Debt Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Short-Term Debt
- - - -

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LENZ Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


LENZ Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of LENZ Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


LENZ Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
445 Marine View Avenue, STE No. 320, Del Mar, CA, USA, 92014
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.